Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 2/20 | 0.31 |
| ▸ | PPM1B | O75688 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6478024 | 1.00 | ALDH1A1 (0.34) | ALDH1A1MAPK1FFAR4ACACBKDM4E | |
| SCHEMBL6477628 | 0.88 | CNR2 (0.32) | ALDH1A1MAPK1FFAR4ACACBCNR2 | |
| SCHEMBL6477626 | 0.88 | CNR2 (0.32) | ALDH1A1MAPK1FFAR4ACACBCNR2 | |
| SCHEMBL4705757 | 0.73 | FFAR4 (0.34) | FFAR4ACACB | |
| SCHEMBL6477799 | 0.69 | MGLL (0.47) | ALDH1A1RAB9A | |
| SCHEMBL6488898 | 0.69 | MAOA (0.50) | ALDH1A1PPM1B | |
| SCHEMBL6477500 | 0.68 | PTGDR2 (0.44) | ALDH1A1FFAR4RAB9A | |
| SCHEMBL3044040 | 0.68 | FFAR4 (0.30) | FFAR4 | |
| SCHEMBL5378920 | 0.67 | KCNQ3 (0.34) | ALDH1A1RAB9A | |
| SCHEMBL14197158 | 0.67 | KCNQ3 (0.34) | ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6875784-B2 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040127530-A1 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127530-A1 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | OXA1L, CYP1B1, MT-CO1 | ALDH1A1 345/4885MAPK1 1515/4885FFAR4 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.